Ann: GENERAL: PEB: LABTESTS EXCLUSIVE SALES FOR C

• Release Date: 27/03/12 11:29
• Summary: GENERAL: PEB: LABTESTS EXCLUSIVE SALES FOR Cxbladder
• Price Sensitive: No
• Download Document  3.77KB

					

PEB
27/03/2012 09:29
GENERAL

REL: 0929 HRS Pacific Edge Limited

GENERAL: PEB: LABTESTS EXCLUSIVE SALES FOR Cxbladder

NZX ANNOUNCEMENT MARCH 2012

LABTESTS EXCLUSIVE SALES FOR PACIFIC EDGE'S NOVEL DIAGNOSTIC
Cxbladder(R) IN AUCKLAND AND NORTHLAND

Pacific Edge Limited (NZX: PEB) and Labtests Limited are pleased to advise
that they have signed an agreement to market and sell Pacific Edge's (PE)
novel diagnostic test for the detection of bladder cancer, Cxbladder(R)

The agreement gives Labtests the exclusive right to market and sell
Cxbladder(R) to urologists and general practitioners (GPs) in the Auckland
and Northland regions. Pacific Edge will provide all laboratory analytical
services from its diagnostic laboratory based in Dunedin for all the tests
sold by Labtests. Pacific Edge will retain the rights to the rest of New
Zealand for the marketing and sale of Cxbladder(R).  The terms of the license
agreement are confidential.

Labtests, which is owned by the Healthscope Group a leading private health
care provider in Australia, is a NZ based pathology services provider
contracted to the Auckland Regional District Health Board to supply services
to 1.5 million Aucklanders and Northlanders. Labtests is IANZ accredited and
employs 600 staff including15 pathologists. A team of Labtests's medical
liaison specialists will provide regular coverage of clinicians and GP's in
these regions.

Cxbladder(R) is a non-invasive, accurate test that enables the early
detection of bladder cancer from a small volume of urine. It provides general
practitioners and urologists with a quick, cost effective and accurate
measure of the presence of the cancer and provides urologists with the
opportunity to reduce their reliance on the need for invasive tests such as
cystoscopy. The recently completed multi-centre international clinical study
recruited 467 patients from Australia and New Zealand. Results showed that
Cxbladder(R) outperformed all of the benchmark technologies in the trial and
detected nearly all of the tumours of concern to a urologist; 100% of T1,
100% of T2, 100% of Tis and 96% of all high grade tumours.

Bladder cancer is the cancer with the 9th highest incidence globally and has
the 5th highest incidence for men. One of the early symptoms of bladder
cancer is the presence of blood in the urine, haematuria. People with
haematuria often present to their general practitioner before being referred
to a urologist.

Bladder cancer has the highest total medical costs of any cancer and in the
US, approaching US$200,000 per patient from detection until death. In
Australia and New Zealand there are expected to be in excess of 55,000 people
presenting to their healthcare provider this year with blood in their urine,
(haematuria) often a precursor to bladder cancer, and it is anticipated that
the Australian and New Zealand healthcare system could invest in excess of
$50 million per annum in investigating haematuria. Cxbladder(R) is expected
to completely replace cytology and be used to complement cystoscopy in the
clinical care path for patients presenting to clinicians with haematuria.

Pacific Edge Limited (PEB):
Pacific Edge (PE) is a New Zealand based biomedical and diagnostics company
specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer.
Products in development and in clinical trials are accurate and simple to use
genomic and proteomic tools for the earlier detection, improved
characterisation and better management of gastric, bladder, colorectal,
endometrial cancers and melanoma. The company has recently completed and
released its first product for the detection of bladder cancer, Cxbladder(R).

D Darling
Chief Executive Officer
Pacific Edge Ltd
End CA:00221188 For:PEB    Type:GENERAL    Time:2012-03-27 09:29:43